世界のBCL-2（B細胞リンパ腫2）阻害薬市場は、予測期間中に約12.60 %のCAGRで推移し、2022年から2026年の間に14億3,000万USドルの成長が見込まれています。本レポートは、総体的な分析、市場規模と予測、動向、成長推進要因、課題、および約25社のベンダーを対象とするベンダー分析を提供しています。
本レポートは、現在の世界市場シナリオ、最新動向と成長推進要因、および全体的な市場環境に関する最新の分析を提供します。市場は、老人人口の増加と血液悪性腫瘍に対する意識の高まりによって推進されています。 また、高齢者人口の増加は市場の成長を後押しすることも予想されます。
本調査では、BCL-2（B細胞リンパ腫2）阻害薬の高い標的親和性と特異性が、今後数年間のBCL-2（B細胞リンパ腫2）阻害薬市場の成長を促進する主要な理由の1つであると特定しています。
Technavio社の堅牢なベンダー分析は、クライアントが市場での地位を向上させるのに役立つように設計されており、これに沿って、主要なBCL-2（B細胞リンパ腫2）阻害薬市場ベンダーの詳細な分析を提供します
この調査は、業界の主要な参加者からの情報を含む、一次情報と二次情報の客観的な組み合わせを使用して実施されました。本レポートには、主要ベンダーの分析に加えて、包括的な市場とベンダー情勢が含まれています。
TechNavio社は、利益、価格設定、競争、プロモーションなどの主要なパラメーターの分析により、複数のソースからのデータの調査、統合、および集計により、市場の詳細な状況を提示します。また、業界の主要なインフルエンサーを特定することにより、さまざまな市場の側面を提示します。提示されたデータは、包括的で信頼性が高く、一次および二次の広範な調査の結果です。Technavio社の市場調査レポートは、完全な競争環境と、質的および量的調査を使用して正確な市場成長を予測する詳細なベンダー選択の調査手法と分析を提供します。
目次
1. Executive Summary
1.1 Market Overview
Exhibit 01: Key Finding 1
Exhibit 02: Key Finding 2
Exhibit 03: Key Finding 3
Exhibit 04: Key Finding 5
Exhibit 05: Key Finding 6
Exhibit 06: Key Finding 7
Exhibit 07: Key Finding 8
2. Market Landscape
2.1 Market ecosystem
2.1.1 Parent Market
Exhibit 08 Parent market
Exhibit 09: Market characteristics
2.2 Value Chain Analysis
Exhibit 10: Value Chain Analysis: Pharmaceuticals
2.2.1 Research and development (R&D) and drug discovery:
2.2.2 Integration and product development:
2.2.3 Manufacturing:
2.2.4 Outbound logistics:
2.2.5 Marketing and sales:
2.2.6 Support services:
2.2.7 Innovation
3. Market Sizing
3.1 Market definition
Exhibit 11: Offerings of vendors included in the market definition
3.2 Market segment analysis
Exhibit 12: Market segments
3.3 Market size 2021
3.4 Market outlook: Forecast for 2021 - 2026
Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)
4. Five Forces Analysis
4.1 Five Forces Summary
Exhibit 15: Five forces analysis 2021 - 2026
4.2 Bargaining power of buyers
Exhibit 16: Bargaining power of the buyer
4.3 Bargaining power of suppliers
Exhibit 17: Bargaining power of the supplier
4.4 Threat of new entrants
Exhibit 18: Threat of new entrants
4.5 Threat of substitutes
Exhibit 19: Threat of substitutes
4.6 Threat of rivalry
Exhibit 20: Threat of rivalry
4.7 Market condition
Exhibit 21: Market condition - Five forces 2021
5. Market Segmentation by Product
5.1 Market segments
Exhibit 22: Product Market share 2021 - 2026 (%)
5.2 Comparison by Product
Exhibit 23: Comparison by Product
5.3 Combination therapy - Market size and forecast 2021-2026
Exhibit 24: Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibit 25: Combination therapy - Year-over-year growth 2021-2026 (%)
5.4 Monotherapy - Market size and forecast 2021-2026
Exhibit 26: Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibit 27: Monotherapy - Year-over-year growth 2021-2026 (%)
5.5 Market opportunity by Product
Exhibit 28: Market opportunity by Product
6. Customer landscape
Technavio-s customer landscape matrix comparing Drivers or price sensitivity, Adoption lifecycle, importance in customer price basket, Adoption rate and Key purchase criteria
6.1 Overview
Exhibit 29: Customer landscape
7. Geographic Landscape
7.1 Geographic segmentation
Exhibit 30: Market share By Geographical Landscape 2021-2026 (%)
7.2 Geographic comparison
Exhibit 31: Geographic comparison
7.3 North America - Market size and forecast 2021-2026
Exhibit 32: North America - Market size and forecast 2021-2026($ million)
Exhibit 33: North America - Year-over-year growth 2021-2026 (%)
7.4 Europe- Market size and forecast 2021-2026
Exhibit 34: Europe - Market size and forecast 2021-2026 ($ million)
Exhibit 35: Europe- Year-over-year growth 2021-2026 (%)
7.5 Asia- Market size and forecast 2021-2026
Exhibit 36: Asia - Market size and forecast 2021-2026 ($ million)
Exhibit 37: Asia - Year-over-year growth 2021-2026(%)
7.6 ROW - Market size and forecast 2021-2026
Exhibit 38: ROW - Market size and forecast 2021-2026 ($ million)
Exhibit 39: ROW - Year-over-year growth 2021-2026 (%)
7.7 Key leading countries
Exhibit 40: Key leading countries
7.8 Market opportunity By Geographical Landscape
Exhibit 41: Market opportunity By Geographical Landscape ($ million)
8. Drivers, Challenges, and Trends
8.1 Market drivers
8.1.1 Rise in geriatric population
8.1.2 Growing awareness about hematological malignancies
8.1.3 High target affinity and specificity of BCL-2 inhibitors
8.2 Market challenges
8.2.1 Availability of substitutes
Exhibit 42: Some of the substitute drugs for BCL-2 inhibitor lead molecule:
8.2.2 Adverse effects of BCL-2 inhibitors
8.2.3 Drug resistance
Exhibit 43: Impact of drivers and challenges
8.3 Market trends
8.3.1 Increase of patient assistance programs
8.3.2 Growing approval of combination therapy
8.3.3 Development of novel formulations
9. Vendor Landscape
9.1 Overview
Exhibit 44: Vendor landscape
9.2 Landscape disruption
Exhibit 45: Landscape disruption
Exhibit 46: Industry Risk
9.3 Competitive Scenario
10. Vendor Analysis
10.1 Vendors covered
Exhibit 47: Vendors covered
10.2 Market positioning of vendors
Exhibit 48: Market positioning of vendors
10.3 AbbVie Inc.
Exhibit 49: AbbVie Inc. - Overview
Exhibit 50: AbbVie Inc. - Product and service
Exhibit 51: AbbVie Inc. - Key offerings
10.4 Ascentage Pharma Group International
Exhibit 52: Ascentage Pharma Group International - Overview
Exhibit 53: Ascentage Pharma Group International - Business segments
Exhibit 54: Ascentage Pharma Group International - Key offerings
Exhibit 55: Ascentage Pharma Group International - Segment focus
10.5 AstraZeneca Plc
Exhibit 56: AstraZeneca Plc - Overview
Exhibit 57: AstraZeneca Plc - Product and service
Exhibit 58: AstraZeneca Plc - Key offerings
10.6 BioGene Ltd.
Exhibit 59: BioGene Ltd. - Overview
Exhibit 60: BioGene Ltd. - Product and service
Exhibit 61: BioGene Ltd. - Key offerings
10.7 F. Hoffmann La Roche Ltd
Exhibit 62: F. Hoffmann La Roche Ltd. - Overview
Exhibit 63: F. Hoffmann La Roche Ltd. - Business segments
Exhibit 64: F. Hoffmann La Roche Ltd. - Key offerings
Exhibit 65: F. Hoffmann La Roche Ltd. - Segment focus
10.8 Servier
Exhibit 66: Servier - Overview
Exhibit 67: Servier - Business segments
Exhibit 68: Servier - Key offerings
Exhibit 69: Servier - Segment focus
11. Appendix
11.1 Scope of the report
11.1.1 Market definition
11.1.2 Objectives
11.1.3 Notes and caveats
11.2 Currency conversion rates for US$
Exhibit 70: Currency conversion rates for US$
11.3 Research Methodology
Exhibit 71: Research Methodology
Exhibit 72: Validation techniques employed for market sizing
Exhibit 73: Information sources
11.4 List of abbreviations
Exhibit 74: List of abbreviations
Exhibits
Exhibits1: Key Finding 1
Exhibits2: Key Finding 2
Exhibits3: Key Finding 3
Exhibits4: Key Finding 5
Exhibits5: Key Finding 6
Exhibits6: Key Finding 7
Exhibits7: Key Finding 8
Exhibits8: Parent market
Exhibits9: Market characteristics
Exhibits10: Offerings of vendors included in the market definition
Exhibits11: Market segments
Exhibits12: Global - Market size and forecast 2021 - 2026 ($ million)
Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
Exhibits14: Five forces analysis 2021 & 2026
Exhibits15: Bargaining power of buyers
Exhibits16: Bargaining power of suppliers
Exhibits17: Threat of new entrants
Exhibits18: Threat of substitutes
Exhibits19: Threat of rivalry
Exhibits20: Market condition - Five forces 2021
Exhibits21: Product - Market share 2021-2026 (%)
Exhibits22: Comparison by Product
Exhibits23: Combination therapy - Market size and forecast 2021-2026 ($ million)
Exhibits24: Combination therapy - Year-over-year growth 2021-2026 (%)
Exhibits25: Monotherapy - Market size and forecast 2021-2026 ($ million)
Exhibits26: Monotherapy - Year-over-year growth 2021-2026 (%)
Exhibits27: Market opportunity by Product
Exhibits28: Customer landscape
Exhibits29: Market share By Geographical Landscape 2021-2026 (%)
Exhibits30: Geographic comparison
Exhibits31: North America - Market size and forecast 2021-2026 ($ million)
Exhibits32: North America - Year-over-year growth 2021-2026 (%)
Exhibits33: Europe - Market size and forecast 2021-2026 ($ million)
Exhibits34: Europe - Year-over-year growth 2021-2026 (%)
Exhibits35: Asia - Market size and forecast 2021-2026 ($ million)
Exhibits36: Asia - Year-over-year growth 2021-2026 (%)
Exhibits37: ROW - Market size and forecast 2021-2026 ($ million)
Exhibits38: ROW - Year-over-year growth 2021-2026 (%)
Exhibits39: Key leading countries
Exhibits40: Market opportunity By Geographical Landscape ($ million)
Exhibits41: Impact of drivers and challenges
Exhibits42: Vendor landscape
Exhibits43: Landscape disruption
Exhibits44: Industry risks
Exhibits45: Vendors covered
Exhibits46: Market positioning of vendors
Exhibits47: AbbVie Inc. - Overview
Exhibits48: AbbVie Inc. - Product and service
Exhibits49: AbbVie Inc. - Key offerings
Exhibits50: AbbVie Inc. - Key customers
Exhibits51: AbbVie Inc. - Segment focus
Exhibits52: Ascentage Pharma Group International - Overview
Exhibits53: Ascentage Pharma Group International - Business segments
Exhibits54: Ascentage Pharma Group International - Key offerings
Exhibits55: Ascentage Pharma Group International - Key customers
Exhibits56: Ascentage Pharma Group International - Segment focus
Exhibits57: AstraZeneca Plc - Overview
Exhibits58: AstraZeneca Plc - Product and service
Exhibits59: AstraZeneca Plc - Key offerings
Exhibits60: AstraZeneca Plc - Key customers
Exhibits61: AstraZeneca Plc - Segment focus
Exhibits62: BioGene Ltd. - Overview
Exhibits63: BioGene Ltd. - Product and service
Exhibits64: BioGene Ltd. - Key offerings
Exhibits65: BioGene Ltd. - Key customers
Exhibits66: BioGene Ltd. - Segment focus
Exhibits67: F. Hoffmann La Roche Ltd. - Overview
Exhibits68: F. Hoffmann La Roche Ltd. - Business segments
Exhibits69: F. Hoffmann La Roche Ltd. - Key offerings
Exhibits70: F. Hoffmann La Roche Ltd. - Key customers
Exhibits71: F. Hoffmann La Roche Ltd. - Segment focus
Exhibits72: Servier - Overview
Exhibits73: Servier - Business segments
Exhibits74: Servier - Key offerings
Exhibits75: Servier - Key customers
Exhibits76: Servier - Segment focus
Exhibits77: Currency conversion rates for US$
Exhibits78: Research Methodology
Exhibits79: Validation techniques employed for market sizing
Exhibits80: Information sources
Exhibits81: List of abbreviations
